Gilead in pact for anti-inflammatory drugs in a deal worth up to $1.7B
Gilead Sciences (NASDAQ:GILD) and Danish pharmaceutical company LEO Pharma on Saturday announced an agreement worth up to ...
Bernstein Sticks to Its Buy Rating for Gilead Sciences (GILD)
In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...
FierceBiotech3d
Galapagos splits in 2, laying off 40% of staff, shrinking pipeline and ending Gilead partnership
After the separation, Gilead will hold around 25% of the outstanding shares in both Galapagos and the spin-off company. While ...
Gilead upgraded by Morgan Stanley on lenacapavir potential
Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...
Zacks.com on MSN1d
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.
ENDPOINTS NEWS2d
Shore­line cuts staff as its part­ner­ship with Gilead­'s Kite is now in flux
Shoreline Biosciences, a gene editing and cell therapy biotech, has let go of staffers dedicated to a cell therapy project ...
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors
This was the stock's fourth consecutive day of losses.
Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise
Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.
The Armenian Reporter1d
ORG Partners LLC Boosts Stake in Gilead Sciences, Inc. (NASDAQ:GILD)
ORG Partners LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 0.3% in the 4th quarter, ...